文献速递神经重症

聚维酮碘冷冻保存自体骨瓣颅骨修补术的长期随访研究

Cranioplasty with autogenous bone flaps cryopreserved in povidone iodine: a long-term follow-up study.
PubMed 文献 · J Neurosurg · 2017-02-10

该回顾性研究分析了188例患者(211个骨瓣)采用聚维酮碘冷冻保存自体骨瓣行颅骨修补术的长期疗效与骨吸收危险因素。中位随访63.1个月时,46.3%的骨瓣出现骨吸收,感染和严重骨吸收发生率低,作者认为该方法是安全有效的。

要点

  • 聚维酮碘冷冻保存自体骨瓣颅骨修补术后感染率3.8%,严重骨吸收率6.0%。
  • 骨吸收CT特征分三型,III型中重度吸收发生率高于I型(p=0.0008)。
  • 骨瓣碎裂及脑室腹腔分流术与骨瓣塌陷发生率升高相关。

核心结论

  • 作者认为,由于感染和严重骨吸收发生率低,聚维酮碘溶液冷冻保存自体骨瓣颅骨修补术安全有效。
  • 骨吸收特征性改变在颅骨修补术后约2个月出现于CT,并在术后约18个月趋于稳定。

研究设计与样本

  • 回顾性分析188例患者(211个骨瓣)采用聚维酮碘冷冻保存自体骨瓣行颅骨修补术的临床资料和随访结果。

主要发现

  • 短期术后并发症包括皮下或硬膜外浆液肿19个骨瓣(9.0%)、硬膜外血肿16个骨瓣(7.6%)和感染8个骨瓣(3.8%)。
  • 8例感染骨瓣需移除及2例2年内死亡患者被排除随访分析;剩余178例患者201个骨瓣随访24-122个月(平均63.1个月)。
  • 201个骨瓣中93个(46.3%)CT显示骨吸收,其中I型55个(59.1%)、II型11个(11.8%)、III型27个(29.0%)。
  • 骨吸收严重程度分级:无吸收108个(53.7%)、轻度66个(32.8%)、中度15个(7.5%)、重度12个(6.0%)。
  • III型骨瓣中重度吸收发生率高于I型(p=0.0008);骨吸收分级与骨瓣位置(p=0.0210)及骨瓣碎裂(p=0.0009)相关;因骨吸收导致骨瓣塌陷的发生率在行脑室腹腔分流术患者中高于未行分流者(p=0.0091)。

临床怎么用

  • 作者认为聚维酮碘冷冻保存自体骨瓣颅骨修补术安全有效;骨吸收CT特征约术后2个月出现,约18个月稳定。
  • 作者指出骨瓣碎裂或行脑室腹腔分流术的患者骨瓣塌陷发生率可能更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE The aim of this study was to investigate the long-term therapeutic efficacy of cranioplasty with autogenous bone flaps cryopreserved in povidone iodine and explore the risk factors for bone resorption. METHODS Clinical data and follow-up results of 188 patients (with 211 bone flaps) who underwent cranioplasty with autogenous bone flaps cryopreserved in povidone-iodine were retrospectively analyzed. Bone flap resorption was classified into 3 types according to CT features, including bone flap thinning (Type I), reduced bone density (Type II), and osteolysis within the flaps (Type III). The extent of bone flap resorption was graded as mild, moderate, or severe. RESULTS Short-term postoperative complications included subcutaneous or extradural seroma collection in 19 flaps (9.0%), epidural hematoma in 16 flaps (7.6%), and infection in 8 flaps (3.8%). Eight patients whose flaps became infected and had to be removed and 2 patients who died within 2 years were excluded from the follow-up analysis. For the remaining 178 patients and 201 flaps, the follow-up duration was 24-122 months (mean 63.1 months). In 93 (46.3%) of these 201 flaps, CT demonstrated bone resorption, which was classified as Type I in 55 flaps (59.1%), Type II in 11 (11.8%), and Type III in 27 (29.0%). The severity of bone resorption was graded as follows: no bone resorption in 108 (53.7%) of 201 flaps, mild resorption in 66 (32.8%), moderate resorption in 15 (7.5%), and severe resorption in 12 (6.0%). The incidence of moderate or severe resorption was higher in Type III than in Type I (p = 0.0008). The grading of bone flap resorption was associated with the locations of bone flaps (p = 0.0210) and fragmentation (flaps broken into 2 or 3 fragments) (p = 0.0009). The incidence of bone flap collapse due to bone resorption was higher in patients who underwent ventriculoperitoneal (VP) shunt implantation than in those who did not (p = 0.0091). CONCLUSIONS Because of the low incidence rates of infection and severe bone resorption, the authors conclude that cranioplasty with autogenous bone flaps cryopreserved in povidone-iodine solution is safe and effective. The changes characteristic of bone flap resorption became visible on CT scans about 2 months after cranioplasty and tended to stabilize at about 18 months postoperatively. The bone resorption of autogenous bone flap may be classified into 3 types. The rates of moderate and severe resorption were much higher in Type III than in Type I. The grade of bone flap resorption was associated with bone flap locations. Fragmented bone flaps or those implanted in patients treated with VP shunts may have a higher incidence of bone flap collapse due to bone resorption.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Zhang J, Peng F, Liu Z, et al. Cranioplasty with autogenous bone flaps cryopreserved in povidone iodine: a long-term follow-up study. J Neurosurg. 2017. PMID: 28186447. doi:10.3171/2016.8.JNS16204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。